Chronic Myeloid Leukemia Following Therapy With Imatinib Mesylate (Gleevec): Bone Marrow Histopathology and Correlation With Genetic Status
نویسندگان
چکیده
منابع مشابه
Hematopathology / IMATINIB MESYLATE (GLEEVEC) FOR CHRONIC MYELOID LEUKEMIA Chronic Myeloid Leukemia Following Therapy With Imatinib Mesylate (Gleevec) Bone Marrow Histopathology and Correlation With Genetic Status
We evaluated bone marrow pathologic features and cytogenetic and molecular genetic status of 13 patients with interferon-resistant, chronic-phase chronic myeloid leukemia (CML), treated with imatinib mesylate (Gleevec). All had morphologic evidence of CML in the blood and bone marrow and were positive for bcr-abl by reverse transcriptase–polymerase chain reaction, fluorescence in situ hybridiza...
متن کاملReversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy.
The effect of imatinib mesylate (imatinib) therapy on angiogenesis and myelofibrosis was investigated and compared with interferon (IFN) and hydroxyurea (HU) in 98 patients with newly diagnosed Philadelphia chromosome-positive/BCR-ABL(+) (Ph(+)/BCR-ABL(+)) chronic myeloid leukemia in first chronic phase and no other pretreatment. By means of immunostaining (CD34) and morphometry, a relationship...
متن کاملMassive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy.
To date, 240 cases of bone marrow necrosis have been reported, of which only 13 were reported in association with chronic myelogenous leukemia (CML). Imatinib mesylate is an agent which can specifically inhibit the activity of tyrosine kinase chimeric protein BCR-ABL which is caused by the balanced translocation between the short arm of chromosome 9, and the long arm of chromosome 22, and is cl...
متن کاملAnalysis of Expression Of SIRT1 Gene In Patients With Chronic Myeloid Leukemia Resistant To Imatinib Mesylate
Background: Chronic myeloid leukemia is a clonal myeloproliferative disease which is characterized by bcr/abl translocation. With the emergence of tyrosine kinase inhibitors such as imatinib mesylate, significant improvement has been made in treatment of this disease. However, drug resistance against this medicine is still an obstacle. SIRT1 is a gene with deacetylase activity which has been de...
متن کاملBone marrow morphological changes in patients of chronic myeloid leukemia treated with imatinib mesylate.
BACKGROUND Imatinib mesylate has shown promising results in chronic myeloid leukemia (CML) in all phases. This drug is an effective treatment for patients with CML in chronic phase as it induces hematological remission in nearly all patients and cytogenetic responses in many. The bone marrow changes produced by this drug are different from the treatment modalities used earlier in CML. MATERIA...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Journal of Clinical Pathology
سال: 2003
ISSN: 0002-9173
DOI: 10.1309/a4rg-p4lf-12gg-h8mw